LiliumX are a recent University of Oxford spinout that drives innovation in bispecific antibody R&D against cancer. We believe that current bispecific antibody R&D is outdated and focused only on limited known biology. We break free of this limitation by using our highly modular high-throughput protein platform to discover novel target combinations to make first-in-class bispecific antibodies with entirely new mechanisms of action. We are backed by mission-driven investors including Y Combinator, Hoxton Ventures, Magnet Ventures, and Acequia Capital. We are disrupting the field of bispecific antibodies and we welcome you to join us in this revolution.